Is a potent and selective inhibitor of MEK1/2
Demonstrated broad anti-proliferative activity in vitro and in vivo
Has well-behaved pharmacokinetic properties across species and possesses a good safety profile in preclinical studies (through chronic 6 month and 9 month GLP toxicology assessments)
Is efficacious against K-Ras and B-Raf mutant tumors (A549, COLO 205) as well as tumors harboring neither mutation (BxPC3) and inhibits tumor growth in numerous other xenograft models ARRY-162, alone and in combination (see poster #2414), is welltolerated in preclinical xenograft models Array's company policy is to not disclose exact structure until the compound is in Phase 2 trials. Disclosure of the structure should not impact the importance or the interpretation of the data we wish to present. 
Activity in BxPC3 Human

ARRY-162: Potency and Selectivity
Enzyme Assays N-terminal 6 His-tagged, constitutively active MEK1 (2-393) was expressed in E. coli and protein is purified by conventional methods. The activity of MEK1 was assessed by measuring the incorporation of γ-33P-phosphate from γ-33P-ATP onto ERK2 in the presence of MEK1.
Cellular Assays
pERK determination: Malme-3M cells seeded in 96-well plates were incubated for 2hr with increasing concentrations of ARRY-162. pERK was measured by an in-cell Western assay using an antibody specific for phospho-p42/44 on ERK 1/2 (thr202/tyr204) and an antibody to normalize to total ERK.
Proliferation assay: Actively proliferating cells (HT29, Malme-3M, SK-MEL-2, COLO 205, SK-MEL-28 and A375) seeded in 96 well plates were incubated with increasing concentrations of ARRY-162 for 72 hours. Cell viability or proliferation was measured using CellTiter-Blue (Promega) percent proliferation was calculated relative to the DMSO control.
In Vivo Tumor Growth Studies
For all studies, Tumor cells were implanted in female nude mice (Taconic Laboratories, Inc. or Charles River Laboratories, Inc.) subcutaneously in the flank, and the tumors were allowed to grow to 150-200 mm3 in size. Then, mice were randomized into treatment groups (n=8) to receive vehicle (1% CMC/0.5% Tween 80; 10 mL/kg) or ARRY-162 (3, 10 or 30 mg/kg). Dosing for all studies was oral, daily for 21 consecutive days. 
